메뉴 건너뛰기
Arthritis and Rheumatism
Volumn 60, Issue 5, 2009, Pages 1565-1566
Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis?
Author keywords

[No Author keywords available]
Indexed keywords

ATLIZUMAB; INTERLEUKIN 1; INTERLEUKIN 6 RECEPTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;
EID: 66049110249     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24474     Document Type: Letter
Times cited : (8)
References (7)
  • 1
    • 0029044362 scopus 로고
    • American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
    • (1995) Arthritis Rheum , vol.38 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3    Bombardier, C.4    Furst, D.5    Goldsmith, C.6
  • 2
    • 2442590862 scopus 로고    scopus 로고
    • New drugs for rheumatoid arthritis
    • Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2007;3501:2167-2179
    • (2007) N Engl J Med , vol.3501 , pp. 2167-2179
    • Olsen, N.J.1    Stein, C.M.2
  • 3
    • 40749114497 scopus 로고    scopus 로고
    • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial
    • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:989-997
    • (2008) Lancet , vol.371 , pp. 989-997
    • Smolen, J.S.1    Beaulieu, A.2    Rubbert-Roth, A.3    Ramos-Remus, C.4    Rovensky, J.5    Alecock, E.6
  • 4
    • 33749363027 scopus 로고    scopus 로고
    • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • and the CHARISMA Study Group
    • Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, and the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829
    • (2006) Arthritis Rheum , vol.54 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3    Pavelka, K.4    Broll, J.5    Balint, G.6
  • 5
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
    • Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-2980
    • (2008) Arthritis Rheum , vol.58 , pp. 2968-2980
    • Genovese, M.C.1    McKay, J.D.2    Nasonov, E.L.3    Mysler, E.F.4    Da Silva, N.A.5    Alecock, E.6
  • 6
    • 0032189103 scopus 로고    scopus 로고
    • The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
    • Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376
    • (1998) J Clin Invest , vol.102 , pp. 1369-1376
    • Fishman, D.1    Faulds, G.2    Jeffery, R.3    Mohamed-Ali, V.4    Yudkin, J.S.5    Humphries, S.6
  • 7
    • 36249013611 scopus 로고    scopus 로고
    • The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6
    • Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, et al. The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet 2007;34:413-418
    • (2007) Int J Immunogenet , vol.34 , pp. 413-418
    • Tischendorf, J.J.1    Yagmur, E.2    Scholten, D.3    Vidacek, D.4    Koch, A.5    Winograd, R.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.